Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 11, 2022Journal of GastroenterologyOpen Access

Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

QZQunfang ZhouChinese PLA General HospitalXWXiaohui WangHunan Normal UniversityRLRuixia LiHarbin Medical University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhou et al. (2022) studied this question.

synapsesocial.com/papers/6a787e2398f24dbf64bdceb5https://doi.org/10.1007/s00535-022-01895-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis2017 · 228 citations
  2. 2Radiofrequency ablation for hepatocellular carcinoma2013 · 88 citations
  3. 3Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma2019 · 195 citations
  4. 4Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion2019 · 562 citations
  5. 5The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma2020 · 300 citations